Breaking News

Aridis Acquires Kenta mAb Portfolio

May 17, 2013

Includes six anti-infectives

Aridis has entered an agreement with Kenta Biotech to acquire Kenta's portfolio of anti-infective human monoclonal antibody (mAb) products and technologies. The portfolio includes six anti-infectives for the treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and respiratory syncytial virus (RSV). Two candidates are in Phase IIa trials for acute pneumonia.
 
Aridis founder and president Eric Patzer said, "We are pleased to complete this transaction and build upon the substantial financial investment and remarkable progress that our colleagues at Kenta Biotech have achieved in creating a portfolio of innovative products.”
 
Kenta chief executive officer Franco Merckling said, "We are pleased to have identified Aridis as the ideal partner to further develop the Kenta technology and project pipeline which has been built over the last seven years. Aridis, a leading San Francisco-area biotech company specializing in novel anti-infectives, is poised to accelerate the development of our drug candidates in both the U.S. and Europe.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent